Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

702
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
702

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Outcomes of Peptide Receptor Radionuclide Therapy in Japanese Patients with Metastatic Rectal Neuroendocrine Tumors.

Cancers·2026
Same author

Reply to the letter regarding "Long-term efficacy and safety of peptide receptor radionuclide therapy in Japanese patients with unresectable neuroendocrine tumor: extension of the Japanese phase I and phase I/II study".

Annals of nuclear medicine·2026
Same author

Analysis of Risk Factors for Post-ERCP Pancreatitis in Patients with Cholangiocarcinoma.

Diagnostics (Basel, Switzerland)·2026
Same author

Evaluation of Reduced Single-Photon Emission Computed Tomography Imaging Protocols and Software Variability in <sup>177</sup>Lu-DOTATATE Dosimetry: Protocol for an Exploratory Observational Trial.

JMIR research protocols·2026
Same author

Long-term efficacy and safety of peptide receptor radionuclide therapy in Japanese patients with unresectable neuroendocrine tumor: extension of the Japanese phase I and phase I/II study.

Annals of nuclear medicine·2026
Same author

Correction to: Policy recommendations for promoting nuclear medicine therapy in Japan 2025, from the Working Group for promoting nuclear medicine therapy of the Japan Society of Clinical Oncology.

International journal of clinical oncology·2026

Related Experiment Video

Updated: Sep 30, 2025

Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy
12:04

Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy

Published on: August 14, 2012

29.0K

Neuroendocrine tumor theranostics.

Yasushi Ichikawa1, Noritoshi Kobayashi1, Shoko Takano2

  • 1Department of Oncology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Cancer Science
|March 10, 2022
PubMed
Summary
This summary is machine-generated.

Theranostics combines therapeutics and diagnostics for simultaneous treatment and imaging. For neuroendocrine tumors, somatostatin receptor-targeted agents offer effective diagnosis and peptide receptor radionuclide therapy.

Keywords:
neuroendocrine tumorpeptide receptor radionuclide therapysomatostatin analogsomatostatin receptor scintigraphytheranostics

More Related Videos

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.3K
Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

1.9K

Related Experiment Videos

Last Updated: Sep 30, 2025

Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy
12:04

Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy

Published on: August 14, 2012

29.0K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.3K
Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

1.9K

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiopharmaceutical Development

Background:

  • Theranostics integrates therapeutic and diagnostic capabilities within single molecular agents.
  • Neuroendocrine tumors (NETs) express specific receptors, like somatostatin receptors, making them suitable for targeted theranostic approaches.
  • Somatostatin analogs are key in NET theranostics, enabling both imaging and targeted radionuclide therapy.

Purpose of the Study:

  • To review the development and application of theranostics for neuroendocrine tumors.
  • To highlight the clinical utility of somatostatin receptor scintigraphy and peptide receptor radionuclide therapy (PRRT) in NET management.
  • To discuss the regulatory landscape and drug lag challenges for radiopharmaceuticals in Japan.

Main Methods:

  • Review of literature on theranostics, focusing on NETs.
  • Analysis of the role of somatostatin analogs in diagnostic imaging (scintigraphy) and therapeutic applications (PRRT).
  • Examination of the historical development and regulatory approval process for radiopharmaceuticals in Japan.

Main Results:

  • Somatostatin receptor scintigraphy and PRRT are established, effective theranostic modalities for NETs.
  • The development and approval of radiopharmaceuticals in Japan face significant regulatory hurdles and delays.
  • Recent progress includes insurance coverage for 177Lu-DOTATATE (Lutathera) in Japan in 2021.

Conclusions:

  • Theranostics represents a significant advancement in cancer therapy, particularly for NETs.
  • Overcoming regulatory challenges is crucial for timely patient access to novel radiopharmaceuticals.
  • Continued development of theranostic agents holds promise for future cancer treatment strategies.